Investigational drug · Phase 2
Redasemtide
Also called: Redasemtide trifluoroacetate, S-005151
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Ischemic Stroke.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "Redasemtide"
First trial start
2023
Jul 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Redasemtide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Ischemic Stroke
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Redasemtide" as an intervention, largest first.
- A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic StrokePivotal-lookingCompleted
ShionogiIndustry
NCT05953480 · 680 participants · Start Jul 14, 2023 · Primary completion Jun 15, 2026
Drug: Redasemtide; Placebo · For: Acute Ischemic Stroke
Sites: Tucson, Arizona; Sarasota, Florida; Augusta, Georgia · 150 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety and efficacy profile of S-005151 (Redasemtide), in patients with chronic liver diseases: phase 2 trial.
Tsuchiya A, Watanabe Y, Kimura N, et al. · Inflamm Regen 2026
Also in development for Acute Ischemic Stroke
- TAK-755rADAMTS13, recombinant ADAMTS13Phase 33 trials
Takeda · Thrombotic Thrombocytopenic Purpura (TTP), Acute Ischemic Stroke
- SovateltideIRL-1620, PMZ-1620Phase 32 trials
Pharmazz, Inc. · Traumatic Brain Injury, Acute Ischemic Stroke, Cerebral Stroke
- JX10Phase 31 trial
Corxel Pharmaceuticals · Acute Ischemic Stroke
- SHPL-49Phase 31 trial
Shanghai Hutchison Pharmaceuticals Limited · Acute Ischemic Stroke
- LT3001Phase 23 trials
Lumosa Therapeutics Co., Ltd. · Acute Ischemic Stroke
- LT3001 DrugPhase 22 trials
Shanghai Pharmaceuticals Holding Co., Ltd · Acute Ischemic Stroke
- B2065Phase 21 trial
Tasly Pharmaceutical Group Co., Ltd · Acute Ischemic Stroke
- BB-031DTRI-031Phase 21 trial
Basking Biosciences, Inc. · Acute Ischemic Stroke
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.